Skip to main
IMDX

Oncocyte Corp (IMDX) Stock Forecast & Price Target

Oncocyte Corp (IMDX) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insight Molecular Diagnostics Inc is positioned for substantial revenue growth, propelled by its advanced diagnostic tests targeting organ transplant monitoring and cancer. The company is exploring an addressable market expansion of approximately 10-20% as it seeks reimbursement for new testing indications related to immunosuppression and rejection monitoring, currently assessed in clinical trials. Furthermore, potential catalysts for financial performance include favorable clinical data presentations, changes in NCCN guidelines, and an acceleration in revenue growth exceeding projections.

Bears say

Insight Molecular Diagnostics Inc. is experiencing a decline in gross margin, which fell to 53.5% in the recent quarter from 67.6% in the previous year, although it exceeded estimates. The company's projected earnings per share have been revised downward to ($1.11) for 2025, reflecting concerns over cash burn and the potential impact of delayed insurer coverage and reimbursement. Additionally, significant risks such as slower physician adoption of new diagnostic tests and the anticipated lack of revenue until mid-2026, pending regulatory clearance for GraftAssureDx, contribute to the negative outlook for the stock.

Oncocyte Corp (IMDX) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oncocyte Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oncocyte Corp (IMDX) Forecast

Analysts have given Oncocyte Corp (IMDX) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Oncocyte Corp (IMDX) has a Strong Buy consensus rating as of Jan 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oncocyte Corp (IMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.